U.S. Markets closed

DelMar Pharmaceuticals, Inc. (DMPI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.27-0.06 (-4.51%)
At close: 3:59PM EDT
People also watch
CAPRDRIOMTNBKTOVDFFN
Full screen
Previous Close1.33
Open1.30
Bid1.26 x 400
Ask1.44 x 1000
Day's Range1.26 - 1.35
52 Week Range1.26 - 7.54
Volume60,032
Avg. Volume130,596
Market Cap17.1M
BetaN/A
PE Ratio (TTM)-2.44
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research6 months ago

    DMPI: Three New Clinical Trials of VAL-083 To be Initiated in 2017

    By Grant Zeng, CFA NASDAQ:DMPI DMPI Begins Dosing of Patients in Phase II Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme On Feb. 13, 2017, DMPI (NASDAQ:DMPI) announced that it ...

  • DelMar Pharmaceuticals Inc (DMPI) Moves Forward With Flagship Chemotherapy Into Phase II
    Insider Monkey6 months ago

    DelMar Pharmaceuticals Inc (DMPI) Moves Forward With Flagship Chemotherapy Into Phase II

    We hear the word chemotherapy all the time. It’s a treatment associated with most cancers. But its ubiquity also masks a hidden secret: The chemotherapy field for brain cancer specifically is woefully out of date. The reason for this has to do with the blood/brain barrier and the need for a medicine that can cross […]

  • Zacks Small Cap Research9 months ago

    DMPI: Three New Clinical Trials with VAL-083 will be Initiated

    As of September 30, 2016, DelMar held $4.8 million in cash. In May 2016, DelMar (DMPI) announced a closing of a private placement of Preferred Shares for gross proceeds of $6.1 million, and the restructuring of 2,095,238 warrants. DelMar has made a great deal of progress in the development of its lead product candidate, VAL-083.  These new funds will allow the company to maintain the momentum it has established in this program through 2017.